Skip to main content

Table 3 Main adverse events of any cause in 12 months

From: Sequential everolimus for angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study

Variables

Standard (n = 23)

Sequential (n = 30)

P value

All Grade

Grade 3/4

All Grade

Grade 3/4

Total

22 (96)

4 (17)

16 (53)

0 (0)

0.010/0.008

Mouth ulceration

22 (96)

2 (9)

12 (40)

0 (0)

 

Hypercholesterolemia

14 (61)

1 (4)

6 (20)

0 (0)

 

Hypertriglyceridemia

11 (48)

1 (4)

7 (23)

0 (0)

 

Menstrual disorder

8 (44)

2 (11)

3 (10)

0 (0)

 

Gastritis

7 (30)

0 (0)

2 (7)

0 (0)

 

Urinary tract infection

7 (30)

1 (4)

3 (10)

0 (0)

 

Headache

5 (22)

0 (0)

2 (7)

0 (0)

 

Non-infectious pneumonia

5 (22)

0 (0)

0 (0)

0 (0)

 

Fatigue

5 (22)

1 (4)

1 (3)

0 (0)

 

Liver dysfunction

5 (22)

0 (0)

2 (7)

0 (0)

 

Renal dysfunction

5 (22)

0 (0)

2 (7)

0 (0)

 

Rash

4 (17)

0 (0)

2 (7)

0 (0)

 

Anemia

4 (17)

0 (0)

2 (7)

0 (0)